tiprankstipranks
Heidelberg Pharma AG (GB:0QW5)
LSE:0QW5

Heidelberg Pharma AG (0QW5) Share Price & Analysis

0 Followers

0QW5 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€2.62 - €4.01
Previous Close€2.99
Volume0.00
Average Volume (3M)15.00
Market Cap
€138.87M
Enterprise Value€74.03M
Total Cash (Recent Filing)€65.01M
Total Debt (Recent Filing)€170.25K
Price to Earnings (P/E)-7.6
Beta0.48
Jul 11, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding46,604,977
10 Day Avg. Volume0
30 Day Avg. Volume15
Standard Deviation0.16
R-Squared0.02
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

0QW5 FAQ

What was Heidelberg Pharma AG’s price range in the past 12 months?
Heidelberg Pharma AG lowest share price was €2.62 and its highest was €4.01 in the past 12 months.
    What is Heidelberg Pharma AG’s market cap?
    Currently, no data Available
    When is Heidelberg Pharma AG’s upcoming earnings report date?
    Heidelberg Pharma AG’s upcoming earnings report date is Jul 11, 2024 which is in 64 days.
      How were Heidelberg Pharma AG’s earnings last quarter?
      Heidelberg Pharma AG released its earnings results on Mar 25, 2024. The company reported -€0.096 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.096.
        Is Heidelberg Pharma AG overvalued?
        According to Wall Street analysts Heidelberg Pharma AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Heidelberg Pharma AG pay dividends?
          Heidelberg Pharma AG does not currently pay dividends.
          What is Heidelberg Pharma AG’s EPS estimate?
          Heidelberg Pharma AG’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Heidelberg Pharma AG have?
          Heidelberg Pharma AG has 46,601,097 shares outstanding.
            What happened to Heidelberg Pharma AG’s price movement after its last earnings report?
            Heidelberg Pharma AG reported an EPS of -€0.096 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Heidelberg Pharma AG?
              Currently, no hedge funds are holding shares in GB:0QW5
              ---

              Heidelberg Pharma AG Stock Smart Score

              7
              Neutral
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Company Description

              Heidelberg Pharma AG

              Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through following business divisions: Customer Specific Research, Diagnostics and Therapeutics.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Genedrive
              Oncimmune Holdings
              InflaRx
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis